Converting HR+ Breast Cancer Into an Individualized Vaccine
Converting HR+ Breast Cancer Into an Individualized Vaccine
Recruiting · NCT03804944 · Registry updated 2026-01-28Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Converting HR+ Breast Cancer Into an Individualized Vaccine | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder | Recruiting | Phase 2 | 2026-01-28 | NCT03804944 |
4 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Celldex Therapeutics | 13 |
| Merck Sharp & Dohme LLC | 650 |
| United States Department of Defense | 319 |
| Weill Medical College of Cornell University | 276 |
8 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Brooklyn Methodist Hospital - NewYork Presbyterian | New York | United States | 8 |
| Cedars-Sinai Medical Center | Los Angeles | United States | 392 |
| Houston Methodist Cancer Center | Houston | United States | 18 |
| Icahn School of Medicine at Mt Sinai | New York | United States | 1 |
| New York Presbyterian Hospital - Queens | New York | United States | 3 |
| UPMC Hillman Cancer Center | Pittsburgh | United States | 330 |
| UT Southwestern Medical Center | Dallas | United States | 2 |
| Weill Cornell Medicine New York Presbyterian Hospital | New York | United States | 1 |